Seelos Therapeutics Inc (SEEL)

[mecosmo2]

apricus,.SA . Shares have lost over 90% of their value over the past three years, but appear to have rebounded over the past few months.

With a PDUFA date of February 17th, this is what we refer to as a defined catalyst opportunity.

Vitaros could do around $200 million in global sales by 2020 (U.S. opportunity of around $150 million).

Vitaros could do especially well in the 18% or so of patients who can't take available ED medications due to contraindications or concurrent disease conditions.
PDUFA . .The Prescription Drug User Fee Act (PDUFA) was a law passed by the United States Congress in 1992 which allowed the Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the new drug approval process